Harmony Biosciences (HRMY) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 51.8% versus a loss of 5.0%. Over five years, HRMY leads with a -13.2% price change compared with -48.4% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.09 billion vs $1.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | PVLA |
|---|---|---|
| Share price | $32.59 | $142.85 |
| Market cap | $1.91B | $2.09B |
| 1-day change | -1.18% | -2.00% |
| YTD return | -12.91% | +36.48% |
| 1-year return | -5.01% | +51.82% |
| 5-year return | -13.21% | -48.39% |
| P/E ratio (TTM) | 10.79 | — |
| Forward P/E | 5.37 | — |
| EPS (TTM) | $3.02 | $-5.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | — |
| Revenue growth (YoY) | +21.51% | — |
| Net income (latest FY) | $158.69M | $-41.72M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | — |
| Net margin | 18.27% | — |
| 52-week high | $43.49 | $179.95 |
| 52-week low | $25.90 | $72.23 |
| Distance from 52-week high | -25.06% | -20.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.53% | +63.42% |
| Average volume | 1.01M | 240.41K |
| Shares outstanding | 58.72M | 14.62M |
| Employees | 293 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed HRMY by 56.8 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
HRMY vs PVLA FAQ
Which is bigger, Harmony Biosciences or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.09B compared with $1.91B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HRMY or PVLA?
PVLA returned +51.82% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.